

This material is intended for UK health journalists only.
For journalistic assessment and preparation before publication.



press release

Wegovy® ▼ (semaglutide injection) now available in the UK through controlled and limited launch

Embargoed until 07:01 BST on Monday 4 September

[Gatwick, UK, September 4 2023] – Novo Nordisk has announced that Wegovy® (semaglutide injection) will be available in the UK from today, Monday September 4 2023, through a controlled and limited launch.

We are dedicated to bringing additional treatment options to people living with obesity and share the Government's ambition to make obesity care accessible where there is high unmet medical need.

We believe the launch of Wegovy® will help provide an additional option to support people living with obesity in the UK and look forward to working with healthcare providers to achieve this.

It will be available in specialist NHS weight management services for people who meet the National Institute for Care and Excellence (NICE) criteria² or privately through a registered healthcare professional. Through the specialist NHS services, patients will also receive support with diet and exercise measures to follow, through a multi-disciplinary team.

As we expect supply to be constrained for the foreseeable future, a proportion of available supply will be allocated for use only within the NHS to allow healthcare professionals to implement NICE guidance. We will continue to work with healthcare professionals to help ensure that patients with the highest unmet medical need are prioritised.

We are closely monitoring Wegovy® demand and are working with regulators and providers to ensure people living with obesity can have access to and remain on treatment.

+++

Wegovy® (semaglutide injection) adult indication¹

Wegovy® (semaglutide injection) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of:

- ≥ 30 kg/m² (obesity), or
- ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity¹

About Novo Nordisk UK

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 59,000 people in 80 countries and markets its products in around 170 countries. For more information, visit www.novonordisk.co.uk

Contact for further information

Media:

Josefine Older Steffensen

+447795640733

IDSF@novonordisk.com

James Watkins

+447584617012

JWTK@novonordisk.com

¹ Wegovy GB Summary of Product Characteristics. June 2023.

² NICE. Semaglutide for managing overweight and obesity. Available at: <https://www.nice.org.uk/guidance/ta875>. Last Accessed: August 2023.